Pulse Biosciences stock
PLSENASDAQPulse Biosciences, Inc., HealthcareISIN US74587B1017
46Score 46 out of 100, Weak
Price and trend
89 / 100
Price history
+248% in one yearThe chart shows daily closes over 10 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 58% above it.
Since February 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 10% below its 52-week high. Largest decline in 10 years: 97% (February 2021 to August 2022).
Chart figures for advanced users
- SMA 50$51.94
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$33.16
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$12.66
- The lowest closing price of the last twelve months.
- Resistance$58.17
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Pulse Biosciences, Inc. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $3.84B, is number 24 of 44 companies in its industry on MEQIRI.
- MEQIRI Score 46 out of 100 (Weak): rank 451 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $189.19M, financial debt $6.36M.Stability 69
Weaknesses
- DilutionShare count up 190% since 2020.Capital allocation 18
- Loss-makingLoss of $83.72M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 90% a year over the last 12 months.Stability 69
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
From 2025 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross −360%, operating −21983%, net −20795%. Last 12 months: net −100%. From 2025 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 18 Feb 2027in 98 days
- Last reported
- 5 Nov 2026EPS reported −$0.32 (expected −$0.31)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.190.0%
- Revenue
- $2.04M0.0%
- Earnings per share
- −$1.250.0%
- Revenue
- $5.64M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +11.9%Study enrollment is still expected to complete in early October as previously revised, three months earlier than the original timeline; operating expenses are expected to stay in the current range.
“Given our enrollment cadence thus far and expectations for site performance in the second half of the study, we are confirming our target completion date of early October, 3 months earlier than our original timeline.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $199,937 in total.
- Teplitsky Liane RaePurchase
1 Sept 2026, Chief Operating Officer
- Shares
- 1,001
- Price
- $49.95
- Value
- $50,000
- Teplitsky Liane RaePurchase
31 Aug 2026, Chief Operating Officer
- Shares
- 1,024
- Price
- $48.80
- Value
- $49,971
- Teplitsky Liane RaePurchase
28 Aug 2026, Chief Operating Officer
- Shares
- 1,034
- Price
- $48.35
- Value
- $49,994
Show 1 more
- Teplitsky Liane RaePurchase
26 Aug 2026, Chief Operating Officer
- Shares
- 1,036
- Price
- $48.24
- Value
- $49,971
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Pulse Biosciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 46
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- Gan & Lee Pharmaceuticals.603087.SS $6.21B56
- TeleflexTFX $6.2B59
- Merit Medical SystemsMMSI $5.28B61
- ICU MedicalICUI $4.46B54
- Envista HoldingsNVST $4.06B72
- Tecan GroupTECN.SW $3.99B53
- Stevanato GroupSTVN $3.8B49
- SCHOTT Pharma AG & Co. KGaA1SXP.F $3.59B69
ETFs that hold Pulse Biosciences
Held by 8 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.04% | 0.30% | €2.17B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.48B |
Show 4 more
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €944.34M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2017)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.